Published on in Vol 5, No 3 (2016): Jul-Sept

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

Angela E Rankine-Mullings   1 , MBBS, MRCPCH ;   Courtney R Little   2 , RN, BSN ;   Marvin E Reid   3 , MBBS, PhD ;   Deanne P Soares   3 , MBBS, DM ;   Carolyn Taylor-Bryan   3 , MBBS, DM ;   Jennifer M Knight-Madden   1 , MBBS, PhD ;   Susan E Stuber   2 , MA ;   Asha V Badaloo   3 , PhD ;   Karen Aldred   1 , MSc ;   Margaret E Wisdom-Phipps   1 , RN, RM ;   Teresa Latham   2 , MA ;   Russell E Ware   2 , MD, PhD

1 Sickle Cell Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica

2 Division of Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States

3 Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica

Corresponding Author: